Biohit Healthcare's antibody and antigen tests for COVID-19 have been awarded ANVISA status, the official stamp of approval from Brazil's Ministry of Health.

Biohit's SARS-CoV-2 IgM/IgG antibody test and SARS-CoV-2 Antigen quantitative assay kit are now included in the select group of COVID-19 tests of allowed manufacturers of goods in Brazil.  

The Biohit rapid lateral-flow antibody kit, which detects both IgM and neutralizing IgG antibodies provides a result in 15 minutes, and is already EUA stamped by US FDA. The ANVISA certification for both the antibody and the antigen test means it meets the standards of Brazilian Class III in vitro diagnostic products.

The SARS-Cov-2 Antigen test shows who has or does not have active COVID-19.

For more information, please use the 'Request Information' button provided below.